Activation of the endothelin A receptor (ET A ) by endothelin-1 (ET-1) mediates events that regulate mitogenesis, apoptosis, angiogenesis and metastasis in tumours. Specific blockade of ET A may have anticancer effects, while retaining beneficial endothelin B receptor (ET B )-mediated effects such as apoptosis and clearance of ET-1. ZD4054 is an orally active, specific ET A antagonist in clinical development. In receptor-binding studies, ZD4054 specifically bound to ET A with high affinity; no binding was detected at ET B . In a randomised placebo-controlled trial in eight healthy volunteers, a single oral dose of ZD4054 reduced forearm vasoconstriction in response to brachial artery infusion of ET-1, thus providing clinical evidence of ET A blockade. ET B blockade was assessed in an ascending, single-dose, placebo-controlled trial in 28 volunteers. For all doses of ZD4054, mean plasma ET-1 concentrations measured at 4 and 24 h were within the placebo reference range (a rise in ET-1 would indicate ET B blockade) and there was no evidence of dose-related changes. These data confirm the specificity of ZD4054 for ET A , with no activity at ET B in a clinical or preclinical setting. As a result of this specificity, ZD4054 has the potential to block multiple ET A -induced pathological processes, while allowing beneficial ET B -mediated processes to continue, which may, in turn, lead to an effective cancer therapy.
There is accumulating evidence to suggest that endothelins, particularly endothelin-1 (ET-1), have a role in regulating the growth and proliferation of tumours . ET-1, produced by tumour cells, exerts its effects primarily by binding to G-protein-coupled receptors on the cell surface (endothelin A receptor (ET A ) and B receptor (ET B )) and modifying the effects of other growth factors (Nelson et al, 1995) .
Binding of ET-1 to ET A and ET B causes distinct and opposing effects on cell growth and survival. In most cells, activation of ET A promotes cell growth , whereas activation of ET B induces cell death via apoptosis (Okazawa et al, 1998) . In addition, binding of ET-1 to ET B results in clearance of ET-1 from the circulation. Overexpression of ET A has been reported in a variety of human tumours and human cancer cell lines, including the prostate, ovary, lung, colon, kidney, cervix and bone . Conversely, ET B expression is reduced in the majority of solid tumours, but is still evident . The balance of ET A and ET B activation in tumour cells appears to be important in progression of most cancers , especially prostate cancer (Kopetz et al, 2002) . Increased expression of ET A relative to ET B could contribute to increased tumour cell survival and growth.
Activation of ET A by ET-1 is reported to result in a number of events involved in the malignant process, including regulating mitogenesis, apoptosis, angiogenesis and tumour metastasis. It triggers a signalling cascade involving growth factors such as epidermal growth factor and insulin-like growth factor-1 (Pirtskhalaishvili and Nelson, 2000) , kinases including protein kinase C and mitogen-activated protein kinase (Bagnato et al, 1997; Bagnato and Catt, 1998) , and induction of immediate-early response genes (c-fos, c-jun and c-myc) that promote cell growth and mitogenesis (Battistini et al, 1993) . Additionally, apoptosis induced by cytotoxic agents is inhibited (Del Bufalo et al, 2002) and angiogenesis promoted (via a vascular endothelial growth factor (VEGF)-mediated mechanism) by activation of ET A Bagnato and Spinella, 2003) . The role of ET A in mediating increased proliferation, resistance to apoptosis and survival of tumour cells, and increased angiogenesis -a process central to tumour growth -makes ET A an attractive target for cancer therapy.
In addition to a role in growth and survival of primary tumours, ET A is an attractive target to prevent the spread and survival of tumour metastases. Activation of ET A induces the expression and activation of tumour proteases (matrix metalloproteinases and urokinase plasminogen activator) that facilitate tumour spread and metastasis (Rosanò et al, 2001) . Furthermore, activation of ET A leads to proliferation of osteoblasts, bone remodelling and release of growth factors that stimulate survival and growth of metastatic tumour cells (Nelson et al, 1999) within prostate cancer metastases in bone. These findings have led to extensive research into the endothelin receptors as a target for anticancer therapies.
Specific blockade of ET A may offer an effective cancer therapy, since the anticancer effects of endothelin antagonists appear to be mediated via ET A blockade. In contrast, antagonism of ET B may lead to undesirable effects, such as inhibition of apoptosis and reduced clearance of ET-1. Thus, an agent with activity purely atthe ET A (i.e. a specific ET A antagonist) would be desirable in an oncology setting. Atrasentan (Abbott Laboratories) is a selective ET A antagonist currently in development which, while selectively binding to ET A , also exhibits antagonism of ET B (Nelson, 2003) , leading to increased plasma ET-1 levels Nelson, 2003) . These findings are consistent with the binding affinities reported for atrasentan (0.034 and 63.3 nM for ET A and ET B , respectively). ZD4054 (AstraZeneca) is an orally active ET A antagonist in early clinical development for the treatment of cancer, which has recently been granted fast-track status by the FDA. The synthesis and molecular characterisation of ZD4054, a nonpeptide ET A antagonist, has been described previously (Bradbury et al, 1997) . ZD4054 binds to ET A with high affinity and has no detectable affinity for ET B . In preclinical studies, ZD4054 specifically inhibits ET A -mediated antiapoptotic effects, but not ET B -mediated proapoptotic effects in human smooth muscle cells (Curtis et al, 2004; Dreicer et al, 2005) , blocks ET A -mediated activation of p44/42 mitogen-activated protein kinase in murine osteoblast cells and inhibits ET-1 induced proliferation of human immature pre-osteoblast cells . Importantly, ZD4054 inhibits growth of tumour xenografts in mice and enhances the cytotoxicity of paclitaxel in ovarian carcinoma in vitro and in vivo (Rosanò et al, 2005) . This paper reports the results of studies that were conducted to confirm the specificity of ZD4054 for ET A in a clinical setting.
MATERIALS AND METHODS

Receptor-binding assays
The inhibition by ZD4054 (varying concentrations) of 125 iodine-ET-1 binding to cloned human ET A and ET B was assessed using standard radioligand-binding techniques. Human recombinant ET A or ET B was expressed in mouse erythroleukaemic cells, and cell membranes prepared for competitive binding studies using 125 iodine-ET-1 as the radioligand. Incubations were carried out in triplicate in the presence of ZD4054, 100 pM to 100 mM in half-log increments, and inhibition of ET-1 binding was expressed as the geometric mean pIC 50 value (concentration to inhibit 50% of binding) with a 95% confidence interval (CI). The affinity of ZD4054 for cloned human ET A was also assessed -using the equation of Cheng and Prusoff (1973) to determine the equilibrium dissociation constant (K i ) -in a further receptor-binding screen utilising a greater number of concentration -response curves determined in three separate studies.
Healthy volunteer study of forearm vasoconstriction to assess interaction with ET A
ET-1 causes vasoconstriction predominantly by activation of ET A on vascular smooth muscle (Spratt et al, 2001) . Therefore, inhibition of ET-1-induced vasoconstriction, measured by venous occlusion plethysmography (Wilkinson and Webb, 2001) , would provide clinical evidence of ET A blockade.
A single-dose, double-blind, placebo-controlled randomised trial was undertaken in eight healthy adult male volunteers to study the effect of ZD4054 on ET-1-mediated forearm vasoconstriction. All volunteers had previously demonstrated a mean 25 -75% reduction in forearm blood flow (measured using standard strain gauge venous occlusion plethysmography) in response to a 120-min brachial artery infusion of ET-1. The effects of two oral doses of ZD4054 (10 and 30 mg) on ET-1-induced vasoconstriction were compared with placebo. Over nonconsecutive days, each volunteer received both doses of ZD4054 and placebo. The study was limited to two active doses and placebo due to the invasive nature and high technical difficulty of the brachial artery infusions and forearm vasoconstriction assessment. A 120-min brachial artery infusion of ET-1 (2.5 pmol min À1 ) was given to resting subjects, commencing 2 h after dosing with ZD4054 or placebo. The degree of forearm vasoconstriction measured between 90 and 120 min of the infusion (at 10-min intervals over a 30-min period) was compared between dose groups. The summary measure for statistical analyses was the percentage change in forearm blood flow. This measure was derived from the change from baseline (immediately prior to ET-1 infusion) in the mean area under the effect curve (forearm blood flow response) from 90 to 120 min (AUEC 90À120 ) relative to the noninfused arm for each volunteer at each dose level vs placebo. Previous studies have shown that AUEC 90À120 represents the most sensitive measure of ET A antagonism as ET-1-induced vasoconstriction is usually maximal after 90 min (Strachan et al, 2002) . Treatment and dose effects were compared using analysis of variance (ANOVA), fitting effects for subject and dose level.
Healthy volunteer study of plasma ET-1 levels to assess interaction with ET B A randomised, ascending, single-dose, double-blind, placebocontrolled study was undertaken in 28 healthy adult male volunteers. Oral doses of ZD4054 evaluated were 2.5, 10, 20, 30, 60, 120, 150 and 240 mg, with dose escalation continued based on tolerability until the maximum tolerated dose had been defined. The planned dose escalation sequence was from 120 to 240 mg ZD4054. However, the 240 mg dose was not tolerated; so the dose of 150 mg ZD4054 was investigated to further define the maximum tolerated dose. Volunteers were randomised approximately 3 : 1 to ZD4054 or placebo on each study day. Each cohort of volunteers was dosed consecutively on three separate study days, with a minimum of 14 days between doses in the same group. Doses of ZD4054 given were: group 1 (n ¼ 9) 2.5, 60 and 150 mg; group 2 (n ¼ 9) 10, 20 and 120 mg; group 3 (n ¼ 10) 30 and 240 mg. Blood samples were collected for measurement of plasma ET-1 (and its precursor, Big-ET-1), at baseline and at 4 and 24 h post-dose. An increase in ET-1 was taken as evidence of ET B blockade. ET-1 and big ET were extracted from plasma using an acetic acid extraction technique described by Rolinski et al (1994) . Concentrations of ET-1 and big ET-1 in the extract were determined by radioimmunoassay using a methodology based on commercially available assay kits (Peninsula Laboratories Inc., San Carlos, CA, USA). Briefly, 100 ml of standard, sample or control was incubated with the appropriate antibody overnight. Samples were incubated with a known concentration of radio-labelled ET-1 or big ET-1 for a further 16 h and the immune complexes were precipitated with Amerlext (Amersham Plc, Amersham, UK) donkey anti-rabbit antibody. The sensitivities of the assays, defined as two standard deviations above the zero binding, were 0.25 pg ml À1 for ET-1 and 1 pg ml À1 for big ET-1. Both clinical studies were approved by an Independent Ethics Committee and all subjects gave written informed consent. The study was performed in accordance with ethical principles originating in the Declaration of Helsinki and consistent with ICH/Good Clinical Practice, applicable regulatory requirements and AstraZeneca's policy on bioethics.
RESULTS
Receptor-binding assays
ZD4054 potently inhibited the binding of 125 iodine-ET-1 to cloned human ET A expressed in mouse erythroleukaemic cells, showing that ZD4054 has high affinity for ET A . The pIC 50 for ZD4054 at the ET A (geometric mean) was 8.27 nM (95% CI: 8.23, 8.32 nM) (n ¼ 4). Displacement curves were normal, with slopes close to unity. In the multi-receptor binding screen, pIC 50 values for ZD4054 at ET A were 22, 27 and 13 nM (mean value 21 nM) ( Table 1 ). The K i values measured in the same studies were 13, 17 and 8 nM (mean value 13 nM).
In contrast, ZD4054 had no measurable affinity for cloned human ET B , with a mean displacement of only 1.270.7% (n ¼ 3) of 125 iodine-ET-1 at a concentration of 100 mM ZD4054. This level of displacement is within the background range and is likely to be caused by assay variability. In the multi-receptor-binding screen, ZD4054 was inactive at ET B at a concentration of 10 mM (Table 1) .
These data show that ZD4054 is a high-affinity ligand for ET A , with no measurable affinity for ET B .
Healthy volunteer study of forearm vasoconstriction to assess interaction with ET A
In volunteers given placebo, forearm blood flow was reduced by approximately 40% in response to brachial artery infusion of ET-1.
ZD4054 inhibited this response to ET-1 ( Figure 1A) . The mean AUEC (90À120 min) corresponding to the forearm blood flow for each dose and placebo is shown in Table 2 and the AUEC (90À120 min) for individual patients at each dose level is shown in Figure 1B to illustrate the variability between individual volunteers. Administration of ZD4054 (10 or 30 mg; combined data) produced a statistically significant absolute reduction in vasoconstriction of 18.8% (P ¼ 0.021) when compared to placebo. Pairwise comparison showed that administration of ZD4054 (30 mg) produced a statistically significant absolute reduction in vasoconstriction of 23.7% (P ¼ 0.0125), representing a 63% decrease in vasoconstriction relative to placebo. ZD4054 (10 mg) resulted in a numerical decrease in vasoconstriction compared with placebo, which did not reach statistical significance (P ¼ 0.10). Peak plasma concentrations were reached by 1.75 and 2.5 h post-dosing and the mean plasma half-life of ZD4054 was 9.10 and 9.65 h for the 10 and 30 mg doses, respectively.
These results provide evidence that ZD4054 is an ET A antagonist in healthy volunteers. ET-1 (2.5 pmol min À1 ) was administered over 2 h after treatment with placebo or ZD4054. AUEC 90 -120 min ¼ mean area under the effect curve from 90 to 120 min. Healthy volunteer study of plasma ET-1 levels to assess interaction with ET B
Following administration of ZD4054 (2.5 -240 mg), mean values for plasma ET-1 were within the placebo range at both 4 and 24 h post-dose (Figures 2A and B) . The placebo range was defined by the 2.5 and 97.5% percentiles of the pre-dose and placebo (drug naïve) samples. Within this study, ZD4054 was well-tolerated at single doses up to and including 120 mg; dose escalation was limited by headache, nausea and vomiting. Based on a rise in mean ET-1 values (Figures 2A and B) or percentage change from baseline (data not shown), there was no evidence of a dose-related response across the 2.5 -240 mg (twice the maximum well-tolerated dose) dose range tested. Since peak plasma concentrations of ZD4054 were reached by approximately 2 h post-dose, any impact on ET-1 clearance and plasma concentration of ET-1 can be expected to be detectable at 4 h post-dose. However, no consistent profile was observed when comparing the 4-and 24-h time points at each dose (Figures 2A or B) . Similarly, there was no evidence of an increase in levels of Big ET-1, the precursor for ET-1 (data not shown). These data, showing the inability of ZD4054 to alter plasma concentrations of ET-1 (a biomarker of ET B blockade in vivo (Strachan et al, 1999) ) in healthy volunteers, demonstrate the specificity of ZD4054 for ET A in a clinical setting.
DISCUSSION
Studies have shown that activation of ET A by ET-1 results in a number of events that promote cell growth and mitogenesis (Battistini et al, 1993; Bagnato et al, 1997; Bagnato and Catt, 1998; Pirtskhalaishvili and Nelson, 2000) , inhibit apoptosis induced by cytotoxic agents (Del Bufalo et al, 2002) and facilitate angiogenesis Bagnato and Spinella, 2003) . Activation of ET A by ET-1 also induces tumour proteases that facilitate tumour metastasis (Rosanò et al, 2001) , and causes proliferation of osteoblasts, bone remodelling and release of growth factors that stimulate survival and growth of metastatic tumour cells (Nelson et al, 1999) . As a result, ET A is an attractive target for cancer therapy. Specific blockade of ET A has the potential to mediate anticancer effects, while allowing beneficial effects such as apoptosis and clearance of ET-1 that are mediated by ET B to proceed.
Results of the in vitro binding studies presented here show ZD4054 to be a potent and specific ET A antagonist, exhibiting high-affinity binding to ET A , with no measurable affinity for ET B at a concentration of 10 mM. These results are consistent with previously reported molecular characterisation (Bradbury et al, 1997) , and the results of functional assays showing that ZD4054 specifically inhibited ET A -mediated antiapoptotic effects, but not ET B -mediated proapoptotic effects, in human and rat smooth muscle cells (Curtis et al, 2004; Dreicer et al, 2005) .
The experimental forearm vasoconstriction model is currently accepted as a standard technique for the investigation of vascular pharmacology and the impact of intra-arterial drug infusion in man (Wilkinson and Webb, 2001) . Results using this model show ZD4054 to be a pharmacologically active ET A antagonist, acting in a dose-related manner to reduce ET-1-induced vasoconstriction. This vasoconstriction is mediated primarily by ET-1 selective, vascular smooth muscle ET A (Spratt et al, 2001) . Although these results clearly demonstrate ET A antagonism in vivo, they do not give any information regarding the affinity of ZD4054 for ET B . Thus, a further volunteer study was undertaken to explore the specificity of ZD4054 for ET A .
In healthy volunteers, the concentration of circulating ET-1 has been established as a biomarker of ET B blockade in vivo (Strachan et al, 1999) . In this setting, a rise in plasma ET-1, particularly without an accompanying rise in Big ET-1, indicates ET B inhibition. In the healthy volunteer study reported here, no evidence of ZD4054-induced ET B inhibition was detected; mean plasma levels of ET-1, at all doses of ZD4054, were within the placebo range at 4 and 24 h post-dose. No clinically significant rise in plasma ET-1 was observed when ZD4054 was given at doses up to 240 mg (twice the maximum tolerated dose). Furthermore, there was no evidence of a dose-related response based on a rise in mean ET-1 or percentage change from baseline. These data provide evidence that single doses of the ET A antagonist ZD4054 do not inhibit clearance of ET-1, and therefore that ZD4054 does not inhibit ET B in man. Through its specificity for ET A , ZD4054 may offer advantages over other less specific ET A antagonists in the oncology setting. Any degree of binding to ET B has the potential to reduce the efficacy of ET A blockade strategies, both directly through inhibition of ET B -mediated apoptosis and indirectly by reduction of ET-1 clearance, leading to a rise in levels of the ET A ligand, ET-1. Treatment with the selective ET A antagonist atrasentan (10 mg once daily for 28 days) resulted in a significant increase in plasma ET-1 levels in a study of patients with refractory adenocarcinomas . Plasma levels of ET-1 rose linearly with increasing dose of atrasentan (dose range evaluated, 10 -75 mg). This increase in plasma levels of ET-1 suggests reduced clearance of ET-1, an effect that could impair the efficacy of any ET A -blocking strategy. The authors hypothesised that the rise in plasma ET-1 reported with atrasentan was the result of direct ET A blockade . Although it is difficult to extrapolate between patients and healthy volunteers, evidence from the present study shows that blockade of ET A by ZD4054, which has no detectable affinity for ET B (at a concentration of 10 mM), does not result in elevated plasma levels of ET-1. Furthermore, the ability of atrasentan to increase plasma levels of ET-1 has been attributed to blockade of ET B (Nelson, 2003) and suggests that the system is highly sensitive to ET B blockade. To our knowledge, ZD4054 is the only endothelin receptor antagonist in clinical development that targets ET A and does not inhibit ET B at doses under clinical investigation.
In conclusion, volunteer studies and pre-clinical receptor-binding studies confirm that ZD4054 is a potent antagonist of ET A , with no evidence of ET B blockade at doses upto 240 mg in volunteers and at 10 mM in vitro. This lack of affinity for ET B suggests that ZD4054 has the potential to block the multiple pathological processes in malignancy that are mediated by ET A , while allowing the beneficial processes mediated by ET B , such as apoptosis and clearance of ET-1, to proceed. Further studies to assess the clinical impact of specific ET A inhibition by ZD4054 in patients with cancer are ongoing.
